Statistics applied to clinical trials

Statistics Applied to Clinical Trials

Volumn , Issue , 2009, Pages 1-559

  Cleophas, Ton J ^a,b,c   Zwinderman, Aeilko H ^b,d   Cleophas, Toine F ^e   Cleophas, Eugene P ^f  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b Pharmaceutical Medicine   (France)

^c Circulation   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Department of Research Damen Shipyards ^*  (Netherlands)

^f DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892332275     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-9523-8     Document Type: Book

References (467)

1. Kallis F et al. Aspirin versus placebo before coronary artery surgery. Eur J Cardiovasc Surg 1994;8:404-10.
2. Graham WG, Bradley DA. Efficacy of chest physiotherapy and intermittent positive-pressure breathing in the resolution of pneumonia. N Engl J Med 1978;299:624-7.
3. Freirich F. Ethical problem of allowing a random event to determine a patient's treatment. In: Controversies in clinical trials. Saunders, Philadelphia, 1983, p 5.
4. Field A. Discovering Statistics using SPSSD. 2nd Edition, Sage Publications, Thousand Oaks, CA, USA, 2005.
5. Matthews DE, Farewell VT. Using and understanding medical statistics. Karger, Melbourne, Australia, 1996.
6. Cohen A, Posner J. Clinical Drug Research. Kluwer Academic Publishers, Dordrecht, Netherlands, 1995.
7. Bailar JC, Mosteller F. Medical Uses of Statistics. N Engl J Med Books, Waltham, MA, 1986.
8. Swinscow TD. Statistics at square one. BMJ Publishing Group, London, UK, 1996.
9. Glantz SA. Primer of Biostatistics. McGraw-Hill, Singapore, 1992.
10. Motulsky H. Intuitive Statistics. Oxford University Press. New York, 1995.
11. Kuhlmann J, Mrozikiewicz A. What should a clinical pharmacologist know to start a clinical trial? Zuckschwerdt Verlag, Munich, 1998.
12. De Vocht A. SPSS basic guide book. Bijleveld Press, Amsterdam, 1998.
13. Hays WL. Statistics. Holt, Rine and Winston, Toronto, Ontario, 1988.
14. Kirkwood BR. Medical statistics. Blackwell Scientific Publications, Boston, MA, 1990.
15. Petrie A, Sabin C. Medical Statistics at a Glance. Blackwell Science, London, UK, 2000.
16. Riffenburgh RH. Statistics in Medicine. Academic Press. New York, USA, 1999.
17. Utts JM. Seeing through Statistics. Brooks Cole Company, Pacific Grove, CA, 1999.
18. Glaser AN. High Yield Statistics. Lippincott, Williams & Wilkins Baltimore, Maryland, 2001.
19. Petrie A, Sabin C. Medical Statistics at a Glance. Blackwell Science. Malden, MA, 2000.
20. Lu Y, Fang JQ. Advanced Medical Statistics. World Scientific, River Edge, NJ, 2003.
21. Riegelman RK. Studying a study and testing a test. Lippincott Williams & Wilkins, 5th Edition, Philadelphia, 2005.
22. Peat J, Barton B. Medical statistics. Fifth Edition. BMJ Books, Blackwell Publishing, New Delhi, 2005.
23. Campbell MJ. Statistics at square two. BMJ Books, Blackwell Publishing, New Delhi, 2006.
24. BUGS y WinBUGS. http://www.mrc-bsu.cam.ac.uk/bugs http://cran. rproject.org
25. S-plus. http://www.mathsoft.com/splus
26. Stata. http://www.stata.com
27. StatsDirect. http://www.camcode.com
28. StatXact. http://www.cytel.com/products/statxact/statact1.html
29. True Epistat. http://ic.net/~biomware/biohp2te.htm
30. SAS. http://www.prw.le.ac.uk/epidemiol/personal/ajs22/meta/macros.sas
31. SPSS Statistical Software. http://www.spss.com
32. Barnard GA. A review of sequential analysis. J Am Stat Ass 1947;422:658-64.
33. Fisher RA. Statistical methods and scientific inferences. Ed by Oliver & Boyd, Edinburgh, UK, 1956.
34. HOT investigators. The HOT trial. Lancet 1998;87:133-142.
35. Pocock SJ. Clinical trials. A practical approach. New York: Wiley, 1988.
36. Department of Health and Human Services, Food and Drug Administration. International Conference on Harmonisation; Guidance on Statistical Principles for Clinical Trials Availability. Federal Register, 63(179), 1998:49583-49598.
37. Food and Drug Administration. Guideline for Industry. Structure and Content of Clinical Study reports. FDA, 1996: at internet webside WWW.DFA.GOV/CDER/REGGUIDE.HTM/GUIDANCE DOCUMENTS.
38. Pocock SJ. Clinical trials. A practical approach. New York: Wiley, 1988, page 147.
39. Pocock SJ. Clinical trials. A practical approach. New York: Wiley, 1988, page 153.
40. Pocock SJ. Clinical trials. A practical approach. New York: Wiley, 1988, page 149.
41. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-199.
42. Demets DL, Ware JH. Group sequential methods in clinical trials with a one-sided hypothesis. Biometrika, 1980, 67:651-660.
43. Wald A. Sequential Analysis. New York: Wiley, 1947.
44. Armitage P. Sequential Medical Trials. Oxford: Blackwell, 1975.
45. Whitehead J. The design and analysis of sequential clinical trials. Chichester: Ellis Horwood publishers, 1983.
46. Whitehead J. Planning and Evaluating Sequential Trials (PEST, version 3). Reading: University of Reading, 1998 (www.reading.ac.uk/mps/pest/pest.html)
47. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
48. Fuchs HA. The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol 1993;20:1863-6.
49. Pocock SJ. Clinical trials. A practical approach. New York, Wiley, 1988.
50. Furberg C. To whom do the research findings apply? Heart 2002;87:570-4.
51. Julius S. The ALHATT study: if you believe in evidence-based medicine. Stick to it. Hypertens 2003;21:453-4.
52. Cleophas GM, Cleophas TJ. Clinical trials in jeopardy. Int J Clin Pharmacol Ther 2003;41:51-6.
53. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B (1998). Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology, 18(4):274-281.
54. Multiple comparisons boek, Edition University of Leiden, Neth, 1999.
55. SAS Statistical Software, 1998.
56. SPSS Statistical Software, Chicago, IL, 1996.
57. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
58. Fuchs HA. The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol, 1993, 20(11):1863-6.
59. Lauter J. Exact t and F-tests for analyzing studies with multiple endpoints. Biometrics 1996, 52:964-970.
60. Jukema JW, Bruschke AV, Van Boven AJ, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on the regression of coronary artery disease in symptomatic men. Circulation 1995;91:2528-40.
61. SAS. www.sas.com
62. SPSS. www.spss.com
63. S-plus. www.splus.com
64. Stata. www.stata.com
65. Levin RI, Rubin DS. P-value. In: Statistics for management. Eds Levin RI and Rubin DS, Prentice-Hall, New Jersey, 1998, pp 485-496.
66. Utts JM. P-value. In: Seeing through statistics. Ed Utts JM, Duxbury Press, Detroit, 1999, pp 375-386.
67. Cleophas TJ, Zwinderman AH, Cleophas AF. P-values. Review. Am J ther 2004;11:317-322.
68. Cleophas TJ, Zwinderman AH, Cleophas AF. P-values, beware of the extremes. Clin Chem Lab Med 2004;42:300-305.
69. Michelson S, Schofield T. p-values as conditional probabilities. In: The biostatistics cookbook. Eds Michelson S and Schofield T, Kluwer Academic Publishers, Boston, 1996, pp 46-58.
70. Petrie A, Sabin C. Explanation of p-values. In: Medical statistics at glance. Eds Petrie A and Sabin C, Blackwell Science Oxford UK, 2000, pp 42-45.
71. Matthews DE, Farewel VT. P-value. In: Using and understanding medical statistics. Eds Matthews DE and Farewell VT, Karger, New York, 1996, pp15-18.
72. Riffenburgh RH. P-values. In: Statistics in Medicine. Ed Riffenburgh RH, Academic Press, San Diego, 1999, pp 95-96, 105-106.
73. Cleophas TJ, Cleophas GM. Sponsored research and continuing medical education. JAMA 2001;286:302-304.
74. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.
75. Sandham JD, Hull RD, Brand RF, Knox L, Pineo GF, Doig CJ, et al., for the Canadian Critical Care Clinical Trials Group. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5-14.
76. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-1387.
77. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
78. Parisi AF, Folland ED, Hartigan P, on behalf of the Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326:10-16.
79. Seppälä H, Nissinen A, Järvinen H, Huovinen S, Henrikson T, Herva E, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992;326:292-297.
80. Rafal ES, Griffiths CE, Ditre CM, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical retinoin treatment for liver spots associated with photodamage. N Engl J Med 1992;326:368-374.
81. Barrett BJ, Parfrey PS, Vavasour HM, O'Dea F, Kent G, Stone E. A comparison of nonionic, low-osmolality radiocontrast agents with ionic, high-osmolality agents during cardiac catheterization. N Engl J Med 1992;326:431-436.
82. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-782.
83. Motulsky H. P-values, definition and common misinterpretations. In: Intuitive biostatistics. Ed Motulsky H, Oxford University Press, New York, 1995, pp96-97.
84. Cleophas TJ, Cleophas GM. Sponsored research and continuing medical education. JAMA 2001;286:302-4.
85. Julius S. The ALLHAT study: if you believe in evidence-based medicine, stick to it. J Hypertens 2003;21:453-4.
86. Cleophas GM, Cleophas TJ. Clinical trials in jeopardy. Int J Clin Pharmacol Ther 2003;41 51-6.
87. Cleophas TJ. Research data closer to expectation than compatible with random sampling I. Stat Med 2004;23:1015-7.
88. Kieser M, Cleophas TJ. Research data closer to expectation than compatible with random sampling II. Stat Med 2005;24:321-3.
89. Hung H M J, O'Neill RT, Bauer P, Köhne K. The behavior of the p-value when the alternative hypothesis is true. Biometrics 1997;53:11-22.
90. Parisi AF, Folland ED, Hartigan P, on behalf of the Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronay artery disease. N Engl J Med 1992;326:10-6.
91. Seppälä H, Nissinen A, Järvinen H, Huovinen S, Henrikson T, Herva E, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992;326:292-7.
92. Rafal ES, Griffiths CE, Ditre CM, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical retinoin treatment for liver spots associated with photodamage. N Engl J Med 1992;326:368-74.
93. Barrett BJ, Parfrey PS, Vavasour HM, O'Dea F, Kent G, Stone E. A comparison of nonionic, low-osmolality radiocontrast agents with ionic, high-osmolality agents during cardiac catheterization. N Engl J Med 1992;326:431-6.
94. Cleophas TJ, Cleophas GM. Sponsored research and continuing medical education. J Am Med Assoc 2001;286:302-4.
95. Cleophas TJ. Research data closer to expectation than compatible with random sampling. Stat Med 2004;23:1015-7.
96. Julius S. The ALLHAT study: if you believe in evidence-based medicine, stick to it. J Hypertens 2003;21:453-4.
97. Cleophas GM, Cleophas TJ. Clinical trials in jeopardy. Int J Clin Pharmacol Ther 2003;41:51-6.
98. Department of Health and Human Services, Food and Drug Administration. International Conference on Harmonisation; Guidance on Statistical Principles for Clinical Trials Availability. Federal Register, 63(179), 1998:49583-49598.
99. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley, 1989.
100. Box Cox, Statistical Software, University Leyden, Netherlands, 1999.
101. Jukema AJ, Zwinderman AH, et al for the REGRESS study group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-40.
102. Rao CR. Linear Statistical Inference and Its Applications. New York: Wiley, 1973.
103. Owens P, Lyons S, O'Brien E. Ambulatory blood pressure in hypertensive population: patterns and prevalence of hypertensive subforms. J Hypertens 1998;16:1735-45.
104. Zanchetti A. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents. J Hypertens 1997;15:S21-5.
105. Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C, Mancia G. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. J Hypertens 1998;16:733-8.
106. Bleniaszewski L, Staessen JA, Byttebier G, De Leeuw PW, Van Hedent T, Fagard R. Trough-to-peak versus surface ration in the assessment of antihypertensive agents. Blood Press 1997;4:350-7.
107. Van de Luit L, Van der Meulen J, Cleophas TJ, Zwinderman AH. Amplified amplitudes of circadian rhythms and nighttime hypotension in patients with chronic fatigue syndrome; improvement by inopamil but not by melatonin. Eur J Intern Med 1998;9:99-103.
108. Van de Luit L, Cleophas TJ, Van der Meulen J, Zwinderman AH. Nighttime hypotension in mildly hypertensive patients prevented by beta-blockers but not by ACE-inhibitors or calcium channel blockers. Eur J Intern Med 1998;9:251-6.
109. O'Brien E, Atkins N, Staessen J. State of the market, a review of ambulatory blood pressure-monitoring devices. Hypertension 1995;26:835-42.
110. Hays WL. Curvilinear regression. In: Hays WL, Statistics, Holt, Rinehart and Winston, Inc, Chicago, 4th edition, 1988, pp 698-716.
111. SPSS. Statistical Software. Professional Statistics. Chicago, Ill, 2002.
112. Harvard Graphics-3. Statistical Software. Boston MA, Harvard, Inc, 2001.
113. Scheidel B, Lemmer B, Blume H. Influence of time of day on pharmacokinetics and hemodynamic effects of beta-blockers. In: Clinical Chronopharmacology. Munich, Germany: Zuckschwerdt Verlag, 1990; vol 6:75-9.
114. Lemmer B, Scheidel B, Behne S. Chronopharmacokinetics and chronopharmacodynamics of cardiovascular active drugs: propranolol, organic nitrates, nifedipine. Ann NY Acad Sci 1991;618:166-71.
115. Breithaupt-Grogler K, Maleczyk C, Belz GG, Butzer R, Herrman V, Stass H, Wensing G. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist - characterization by use of Schild regression techniques in man. Int J Clin Pharmacol Ther 1997;35:434-41.
116. Debord J, Carpentier N, Sabot C, Bertin P, Marquet P, Treves R, Merle I, Lachatre G. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis. Int J Clin Pharmacol Ther 1998;36:227-30.
117. Kato Z, Fukutomi O, Yamazaki M, Kondo N, Imaeda N, Orii T. Prediction of steady-state serum theophylline concentration in children by first-order and zero-order absorption models. Int J Clin Pharmacol Ther 1994;32:231-4.
118. Mahmood I, Mahayni H. A limited sampling approach in bioequivalence studies: application to low half-life drugs and replicate design studies. Int J Clin Pharmacol Ther 1999;37:275-81.
119. Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 1995;33:164-9.
120. Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B. Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003;41:3-13.
121. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003;41:567-77.
122. Jukema JW, Bruschke AV, Van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, Van Rappard FM, Lie KI. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels (REGRESS Trial). Circulation 1995;91:2528-40.
123. Antman EM, Cohen M, Bernink P, McGabe CH, Horacek T, Papuches G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI Risk score for unstable angina pectors, a method for prognostication and therapeutic decision making. J Am Med Assoc 2000;284:835-42.
124. Hoetner G. The use of logit and probit models in strategic management research. Strat Mgmt J 2007;28:331-43.
125. Rudner LM. Computer adaptive testing. http://edres.org/scripts/cat/ catdemo.htm
126. Boeckman AJ, Sheiner LB, Beal SL. NONMEM User's Guide. NONMEM Project Group, University California, San Francisco, 1992.
127. Davidian M, Giltinan DM. Nonlinear models for repeated measurements data. Chapman and Hall, NY, 1995.
128. Lindstrom MJ, Bates BM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990;46:673-8.
129. Keusch P. Chemical kinetics, rate laws, Arrhenius equation-experiments. http://www.uniregensburg.de/Fakultaeten/nat-Fak-IV/Organische-Chemie/Didaktik. html.
130. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling and drug development. Clin Pharmacol Ther 1984;35:733-41.
131. Fuseau E, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984;35:733-41.
132. Cleophas TJ. The sense and non-sense of regression modeling for increasing precision of clinical trials. Clin Pharmacol Ther 2003;74:295-7.
133. Cleophas TJ. Problems in regression modeling of randomized clinical trials. Int J Clin Pharmacol Ther 2005;43:5-12.
134. Cleophas TJ, Remmert HP, Kauw FH. Celiprolol versus propranolol in unstable angina pectoris. Clin Pharmacol Ther 1996;45:476-3.
135. Van der Vring AF, Cleophas TJ, Zwinderman AH, et al. Different classes of calcium channel blockers in addition beta-blockers for exercise induced angina pectoris. Br J Clin Pharmacol 1999;50:545-60.
136. Cleophas TJ, Zwinderman AH, Cleophas AF. Statistics applied to clinical trials. Springer, New York 2006, pp 141-50.
137. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968;24:295-313.
138. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
139. Rubin DB. Estimating causal effects from large data sets using propensity score. Ann Intern Med 1997;127:757-63.
140. SPSS Statistical Software. http:/www.spss.com
141. Sobb M, Cleophas TJ, Hadj-Chaib A, Zwinderman AH. Clinical trials: odds ratios, why to assess them, and how to do so. Am J Ther 2008;15:44-53.
142. Cleophas TJ, Tuinenburg E, Van der Meulen J, Kauw FH. Wine drinking and other dietary characteristics in males under 60 before and after acute myocardial infarction. Angiology 1996;47:789-96.
143. Soledad Cepeda M, Boston R, Farrer JT, Strom BL. Comparison of logistic regression versus propensity scores when the number of events is low and there are multiple confounders. Am J Epidemiol 2003;158:280-7.
144. Wickramaratne PJ, Holford TR. Confounding in epidemiological studies: the adequacy of the control groups as a measure of confounding. Biometrics 1987;43:751-65.
145. Huppler Hullsiek K, Louis TA. Propensity scores modeling strategies for the causal analysis of observational data. Biostat 2002;3:179-93.
146. Begg CB. Commentary: ruminations on the intent to treat. Control Clin Trials 2000;21:241-3.
147. Beal SL, Sheiner LB. A note on the use of Laplace's approximations for non-linear mixed-effects models. Biometrika 1996;83:447-52.
148. SAS. http://www.prw.le.ac.uk/epidemiol/personal/ajs22/meta/macros.sas
149. Boeckman AJ, Sheiner LB, Beal SL. 1984 NONMEM user guide: part V. NONMEM Project Group, University of California, San Francisco.
150. Cleophas TJ, Zwinderman AH, Cleophas AF. Statistics applied to clinical trials. Springer, New York 2006, 329-36.
151. Riegelman RK. Studying a study and testing a test. Lippincott Williams & Wilkins, Philadelphia, PA, 2005.
152. De Craen A J M, Westendorp R G J. The use of age as a variable in clinical research. Ned Tijdschr Geneeskd 2005;149:2958-63.
153. Hays WL. Random effects and mixed models. Chapter 13. In: Statistics, 4th edition, Holt, Rhinehart and Winnston Inc, Chicago, 1998, pp 479-543.
154. Jukema AJ, Zwinderman AH, et al for the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
155. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop-Hypertension (DASH) randomized clinical trial. Arch Int Med 1999;159:258-93.
156. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-52.
157. Barrett-Connor E. Looking for the pony in the Heart and Estrogen/progestin Replacement Study (HERS) data. Circulation 2002;105:902-3.
158. Chalmers I, Altman DG. Systematic reviews. Edited by Br Med J Books, Bristol Uk, 1996.
159. Thompson SG. Why sources of heterogeneity should be investigated. In: Chalmers I, Altman DG. Systematic reviews. BMJ Publishing Group, London, UK, 1995, pp 48-63.
160. Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow-up in Whitehall study. BMJ. 1991;303:89-92.
161. Stampfer MJ, Goldhaber SZ, Yusuf S. Effects of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med. 1982;307:1180-2.
162. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
163. Glass GV, Smith ML. Meta-analysis of research on class size and achievement. Educational Evolution and Policy Analysis. 1979;1:2-16.
164. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer. J Clin Epidemiol. 1991;44:127-9.
165. Stein RA. Meta-analysis from one FOA reviewer's perspective. Proceedings of the Biopharmaceutical Section of the American Statistical Association. 1988;2:34-8.
166. Zhou X, Fang J, Yu C, Xu Z, Lu Y. Meta-analysis. In: Advanced Medical Statistics, Lu Y and Fang J, eds, World Scientific, River Edge, NJ, 2003, pp 233-316.
167. Turnbul F for the Blood Pressure Lowering Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised controlled trials. Lancet. 2003;362:1527-35.
168. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of the best evidence for clinical decisions. Ann Intern Med. 1998;317:339-42.
169. Straus SE, Sackett DL. Using research findings in clinical practice. BMJ. 1998;317:339-42.
170. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ. 1998;317:465-8.
171. Jones DR. Meta-analysis: Weighing the evidence. Stat Med. 1995;14:137-9.
172. Hunter JE, Schmidt FL. Methods in meta-analysis. 2nd Edition. Sage Public Inc, NY, 2004.
173. Cleophas TJ. Meta-analysis. In: Cleophas TJ, Zwinderman AH, Cleophas AF, eds, Statistics Applied to Clinical Trials, Third Edition, Springer, NY, 2006, pp 205-18.
174. Oxman AD, Guyatt G. Guidelines for reading reviews. Can Med Assoc J. 1988;138:697-703.
175. Greenhalgh T. How to read a paper The Medline database. BMJ. 1997;315:180-3.
176. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized trials in EMBASE. In: Paper presented at the Fourth International Cochrane Colloquium, 20-24 Oct. 1996; Adelaide, Australia, 1996.
177. Cochrane Library. http://www.cochrane.org/cochrane/hbook.htm
178. SAS. http://www.prw.le.ac.uk/epidemiol/personal/ajs22/meta/macros.sas
179. SPSS Statistical Software. http://www.spss.com
180. Cochrane Revman. http://www.cochrane.org/cochrane/revman.htm
181. Stata, sstatistical software for professionals. http://www.stat.com
182. Comprehensive Meta-analysis, by Biostat. http://www.meta-analysis.com
183. Greenland S, Robins JM. Estimation of common effect parameter from sparse follow-up data. Biometrics. 1985;41:55-68.
184. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-71.
185. Ioannides JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:210-28.
186. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on Pub Med: review of publications and survey of authors. BMJ. 2005;330:753-6.
187. Chalmers I, Altman DG. Systematic reviews. BMJ Publishing Group, London, UK, 1995.
188. National Council of Social Studies. Statistical and power analysis software. http://www.ncss.com/metaanal.html
189. Thompson SG. Why sources of heterogeneity should be investigated. In: Chalmers I, Altman DG. Systematic reviews. BMJ Publishing Group, London, UK, 1995, pp 48-63.
190. Dersimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
191. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141-51.
192. Higgins J P T, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
193. Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow-up in Whitehall study. BMJ. 1991;303:89-92.
194. Khan KS. Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Int Med. 1996;156:661-6.
195. Riegelman RK. Meta-analysis. In: Studying a study & testing a test. Riegelman RK, ed, Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2005, pp 99-115.
196. S-plus. http://www.mathsoft.com/splus
197. StatsDirect. http://www.camcode.com
198. StatXact. http://www.cytel.com/products/statxact/statact1.html
199. True Epistat. http://ic.net/~biomware/biohp2te.htm
200. Meta-analysis Mark X. Microsoft's Excel
201. BUGS y WinBUGS. http://www.mrc-bsu.cam.ac.uk/bugs
202. R. http://cran. r-project.org
203. Leandro G. Meta-analysis in medical research. BMJ books, London UK, 2005.
204. Galbraith RF. A note on graphical presentation of estimated odds ratios from several trials. Stat Med. 1988;7:889-94.
205. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, De grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montasli A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ. Cholesterol ester transfer protein TaqiB variant, high density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment. Circulation. 2005;111:278-87.
206. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589-624.
207. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico RD, Bradburn M, Eastwood AJ. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1-148.
208. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313-24.
209. Terrin N, Schmid CH, Griffith JL, D'Agostino RB, Selker HP. External validation of predictive models: a comparison of logistic regression, classification trees, and neural networks. J Clin Epidemiol. 2003;56:721-9.
210. Tang JL, Liu JL. Misleading funnel plots for detection of bias in meta-analysis. J Clin Epidemiol. 2000;53:477-84.
211. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol. 2004;57:683-97.
212. Higgins J P T, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1662-82.
213. Casas JP, Leonelo EB, Humphries SE. Endothelial NO synthase genotype and ischemic heart disease. Circulation. 2004;109:1359-65.
214. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol. 1995;48:45-57.
215. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13:418-26.
216. Le Lorier J, Gregoire G, Benhaddad A, Lapierre J, Derderien F. Discrepancies between meta-analyses nand subsequent large randomized controlled trials. N Engl J Med. 1997;337:536-42.
217. Temple R. Meta-analyses and epidemiological studies in drug development and postmarketing studies. JAMA. 1999;281:841-4.
218. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions; current perspectives. JAMA. 1999;281:824-9.
219. Niemeyer MG, Zwinderman AH, Cleophas TJ, De Vogel EM. Crossover studies are a better format for comparing equivalent treatments than parallel-group studies. In: Kuhlmann J, Mrozikiewicz A, eds, What should a clinical pharmacologist know to start a clinical trial (phase I and II). Munich, Germany, Zuckschwerdt Verlag, 1998, pp 40-48.
220. ScheffèH H. Mixed models. In: ScheffèH H, ed, The analysis of variance. New York, Wiley & Sons, 1959, pp 261-91.
221. Cleophas TJ. Crossover studies: a modified analysis with more power. Clin Pharmacol Ther 1993;53:515-20.
222. Willan AR, Pater JL. Carryover and the two-period crossover clinical trial. Biometrics 1986;42:593-9.
223. Freeman PR. The performance of the two-stage analysis of two-treatment, twoperiod crossover trials. Stat Med 1989;8:1421-32.
224. Fleiss JA. A critique of recent research on the two-treatment crossover design. Control Clin Trials 1989;10:237-41.
225. Senn S. The AB/BA crossover: past, present and future. Stat Methods Med Res 1994;3:303-24.
226. Grieve AP. Bayesian analyses of two-treatment crossover studies. Stat Methods Med Res 1994;3:407-29.
227. Cleophas TJ, Van Lier HH. Clinical trials with binary responses: power analyses. J Clin Pharmacol 1996;36:198-204.
228. Nies AS, Spielberg SP. Individualization of drug therapy. In: Hardman JL et al., eds, Goodman and Gilman's Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996, pp 43-63.
229. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965;22:469-80.
230. SPSS 8 for Windows 95 and 98, SPSS Benelux, Gorinchem, Netherlands.
231. Hays WL. Statistics. Fort Worth, TX, Holt, Rinehart and Winston, Inc, 4th edition, 1988.
232. Cleophas T J M: A simple analysis of carryover studies with one-group interaction. Int J Clin Pharmacol Ther 1995;32:322-28.
233. Cleophas TJ: Underestimation of treatment effect in crossover trials. Angiology 1990;41:855-64.
234. Brown BW: The crossover experiment for clinical trials. Biometrics 1980;36:69-79
235. Barker M, Hew RJ, Huitson A, Poloniecki J: The two-period crossover trial. Bias 1982;9:67-112.
236. Louis TA, Lavori PW, Bailar JC, Polansky M: Crossover and self-controlled design in clinical research. N Engl J Med 1984;310:24-31.
237. Willan AR, Pater JL: Carryover and the two-period clinical trial. Biometrics 1986;42:593-9.
238. Packer M: Combined beta-adrenergic and calcium entry blockade in angina
239. Fleiss JL: A critique of recent research on the two-treatment crossover design. Control Clin Trials 1989;10:237-43.
240. Freeman PR: The performance of the two-stage analysis of two-treatment, twoperiod crossover trials. Stat Med 1989;8:1421-32.
241. Senn S. Crossover trials in clinical research. Wiley & Sons, Chicester, 1993.
242. Hills M. Armitage P: The two-period crossover trial. Br J Clin Pharmacol 1979;8:7-20.
243. Gart JJ: An exact test for comparing matched proportions in crossover designs. Biometrika 1969;56:57-80.
244. Prescott RJ: The comparison of success rates in crossover trials in the presence of an order effect. Appl Stat 1981;30:9-15.
245. Fidler V: Change-over clinical trials with binary data: mixed model-based comparisons of tests. Biometrics 1984;40:1063-79.
246. Bavry JH: Design Power (TM). Scientific software Inc., 1988, Hillsdale, New Jersey.
247. Cleophas T J M, Tavenier P. Clinical trials of chronic diseases. J Clin Pharmacol 1995;35:594-8.
248. Cleophas T J M, Tavenier P. Fundamental issues of choosing the right type of trial. Am J Ther 1994;1:327-32.
249. Grizzle JE: The two-period change-over design and its use in clinical trials. Biometrics 1965;22:467-80.
250. Cleophas TJ: Between-group disparities in drug response. In: Human Experimentation Boston, Kluwer Academic Publishers, 1999;48-56.
251. Cardiology Dialogue: Edited by Rapid Literature Service. Cologne, Germany: Limbach GMBH, 1994.
252. Nies AS, Spielberg SP: Individualization of drug therapy. In: Hardman JL, Limbird LE, eds. Goodman and Gilman's Pharmacological Basis of Therapeutics New York: McGraw-Hill, 1996:43-63.
253. Grieve AP: Bayesian analysis of two-treatment crossover studies. Stat Meth Med Res 1994;3:407-29.
254. Frieswijk N, Buunk BP, Janssen RM, Niemeyer MG, Cleophas TJ, Zwinderman AH. Social comparison and quality of life: evaluation in patients with angina pectoris. Cardiogram 2000;16:26-31.
255. Zwinderman AH, Niemeyer MG, Kleinjans HA, Cleophas TJ. Application of item response modeling for quality of life assessments in patients with stable angina pectoris. In: Clinical Pharmacology, EDS Kuhlman J, Mrozikiewicz A, Zuckschwerd Verlag, New York, 1999, pp 48-56.
256. Stewart AL, Hays RD, Ware JE. The MOS short form general health survey. Med Care 1988;26:724-35.
257. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L, Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J 1992;305:160-4.
258. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. J Am Med Assoc 1994;272:619-26.
259. Marquis P, Fagol C, Joire JE. Quality of life assessment in patients with angina pectoris. Eur Heart J 1995;16:1554-59.
260. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334:835-40.
261. Thompson DR, Meadows KA, Lewin RJ. Measuring quality of life in patients with coronary heart disease. Eur Heart J 1998;19:693-5.
262. Niemeyer MG, Kleinjans HA, De Ree R, Zwinderman AH, Cleophas TJ, Van der Wall EE. Comparison of multiple dose and once-daily nitrate therapy in 1350 patients with stable angina pectoris. Angiology 1997;48:855-63.
263. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health survey: manual and interpretation guide. Boston. The Health Institute, New England Medical Center, 1993.
264. Albert SM, Frank L, Mrri R, Hylandt, Apolone G, LeplèHge A. Defining and measuring quality of life in medicine. J Am Med Assoc 1998;279:429-31.
265. Cornelisse CJ, Cornelis RS, Devilee P. Genes responsible for familial breast cancer. Pathol Res Pract 1996 Jul; 192(7):684-93.
266. Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, Tops C, Moller P, Fodde R. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998 Aug. 20; 339(8):511-8.
267. Jordan B (Ed.). DNA Microarrays: gene expression applications. Berlin: Springer-Verlag, 2001.
268. Claverie JM. Computational methods for the identification of differential and coordinated gene expression. Hum Mol Genet 2001;8(10):1821-32.
269. McLachlan G. Mixture.model clustering of microarray expression data. Aus Biometrics and New Zealand Stat Association Joint Conference, 2001, Christchurch, New Zealand.
270. Alizadeh et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-11.
271. Eisen M et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA, 1998, 95:14863-14867.
272. Tavazoie et al. Systematic determination of genetic network architecture. Nat Genet 1999, 22:281-5.
273. Tamayo et al. Interpreting patterns of gene-expression with self-organizing maps. Proc Natl Acad Sci USA, 1999, 96:2907-12.
274. Tibshirani et al. Clustering methods for the analysis of DNA microarray data. Tech. rep. Stanford University, Dept of Statistics, Stanford.
275. Pearson K. On a criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it cannot be reasonably supposed to have arisen from random sampling. Philosophical Magazine 1900;50:339-57.
276. Cleophas TJ. Research data closer to expectation than compatible with random sampling. Stat Med 2004;23:1015-17.
277. Cleophas TJ. Clinical trials and p-values, beware of the extremes. Clin Chem Lab Med 2004;42:300-4.
278. Cleophas TJ, Cleophas GM. Sponsored research and continuing medical education. J Am Med Assoc 2001;286:302-4.
279. Furberg C. To whom do the research findings apply? Heart 2002;87:570-574.
280. Levin RI, Rubin DS. Statistics for management. 7th Edition. Edited by Prentice-Hall International, New Jersey, 1998.
281. Hung HM, O'Neill RT, Bauer P, Köhne K. The behavior of the p-value when the alternative hypothesis is true. Biometrics 1997;53:11-22.
282. Kaaraininen I, Sipponen P, Siurala M. What fraction of hospital ulcer patients is eligible for prospective drug trials? Scand J Gastroenterol 1991;26:73-6.
283. Julius S. The ALLHAT study: if you believe in evidence-based medicine, stick to it. J Hypertens 2003;21:453-4.
284. Cleophas GM, Cleophas TJ. Clinical trials in jeopardy. Int J Clin Pharmacol Ther 2003;41:51-6.
285. Cleophas TJ. Research data closer to expectation than compatible with random sampling. Stat Med 2004;23:1015-7.
286. Furberg C. To whom do the research findings apply? Heart 2002;87:570-4.
287. Kaaraininen I, Sipponen P, Siurala M. What fraction of hospital ulcer patients is eligible for prospective drug trials? Scand J Gastroenterol 1991;26:73-6.
288. Cleophas GM, Cleophas TJ. Clinical trials in jeopardy. Int J Clin Pharmacol Ther 2003;41:51-6.
289. Anonymous. KOWA Study Protocol. Pharmanet, Pharm@net
290. Cleophas TJ, Zwinderman AH, Cleophas TF. Example of crossover trial comparing efficacy of a new laxative versus bisacodyl. Statistics applied to clinical trials. Springer, New York 3rd edition, 2006, pp 126-9.
291. Levin RI, Rubin DS. Statistics for management. 7th Edition. Edited by Prentice-Hall International, New Jersey, 1998.
292. Kirkwood BR, Sterne JA. Medical statistics. 2ndEdition. Blackwell Science, Oxford, UK, 2003.
293. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide. Stat Med 2000;19:1141-64.
294. Efron B, Tibshirani RJ. An introduction to the bootstrap. Chapman & Hall, 1993, New York, USA.
295. SPSS Statistical Software 2000 Chicago, IL, USA.
296. Royston P. A toolkit for testing for non-normality in complete and censored samples. The Statistician 1993;42:37-43.
297. Excel. Microsoft Office Online: EXCEL 2003 Home Page
298. Chambers HF, Sande MA. Antimicrobial agents: the aminoglycosides. In Goodman and Gillman's Pharmacological basis of therapeutics, 9th edition, McGraw Hill, New York, USA, 1996; pp 1103-21
299. Cleophas TJ, Van der Meulen J, Zwinderman AH. Nighttime hypotension in hypertensive patients prevented by beta-blockers but not by angiotensin converting enzyme inhibitors or calcium channel blockers. Eur J Intern Med 1998;9:251-7.
300. Neutel JM, Smith DH. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 1997;6:250-6.
301. Hauck WW, Anderson S. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. J Pharmacokin Biopharmaceuticals 1984;12:83-91.
302. Tothfalusi L, Endrenyl L. Evaluation of some properties of individual bioequivalence from replicate-design studies. Int J Clin Pharmacol Ther 2001;39:162-6.
303. Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004;125:1335-42.
304. Petrie A, Sabin C. Medical statistics at a glance. London, UK, Blackwell Science Ltd, 2000.
305. Cleophas TJ. Statistical tables to test data closer to expectation than compatible with random sampling. Clin Res Reg Affairs 2005;22:83-92.
306. Schuirmann DJ. A comparison of the two one-sided test procedures and the proper approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharmaceuticals 1987;15:657-80.
307. Hahn GJ, Meeker WQ. Statistical intervals: a guide for practitioners. New York, John Wiley and Sons, Inc, 1991.
308. Kendall MG, Stuart A. Rank correlation methods. 3rd edition, London, UK, Griffin, 1963.
309. Siegel S. Non-parametric methods for behavioural sciences. New York, McGraw Hill, 1956.
310. Tukey JW. Exploratory data analysis. Reading, MA, Addison-Wesley, 1977.
311. Anonymous http://www.itl.nist.gov/div898/handbook/eda/section3/eda35a.htm
312. Julius S. The ALLHAT study: if you believe in evidence-based medicine. Stick to it. Hypertens 2003;21:453-4.
313. Cleophas GM, Cleophas TJ. Clinical trials in jeopardy. Int J Clin Pharmacol Ther 2003;41:51-6.
314. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 1979;2:420-8.
315. SPSS 10, SPSS Statistical Software, Chicago, IL, version 2004.
316. Anonymous. Calculating Cohen's kappas. http://www.colorado.edu/geography/ gcraft/notes/manerror/html/kappa.html
317. Perloff JK. The clinical recognition of congenital heart disease. Philadelphia, Saunders 1991.
318. Cleophas AF, Zwinderman AH, Cleophas TJ. Reproducibility of polynomes of ambulatory blood pressure measurements. Perfusion 2001;13:328-35.
319. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mecardier A, Poynard T. Intra-laboratory analytical variability of biochemical markers of fibrosis and activity and reference ranges in healthy blood donors. Clin Chem Lab Med 2004;42:323-33.
320. Petrie A, Sabin C. Assessing agreement. In: Medical statistics at a glance. Blackwell Science, London UK, 2000, page 93.
321. Riegelman RK. Studying a study and testing a test. Lippincott Williams & Wilkins, Philadelphia, PA, 2005.
322. Anonymous. Chapter 8: statistical models for prognostication. In: Interactive Textbook. http://symptomresearch.nih.gov. chapter-8.
323. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-316.
324. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC; Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem. 2003;49:1-6
325. STARD Statement. http://www.consortstatement.org/stardstatement.htm
326. Scheidler J, Hricack H, Yu KK, Subak L, Segal MR. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA 1997;278:1096-101.
327. Reitsma J, Glas A, Rutjes A, Scholten R, Bossuyt P, Zwinderman A bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005:58:982-90.
328. Van Houwelingen HC, Zwinderman AH, Stijnen T. A bivariate approach to meta-analysis. Stat Med 1993;12:2273-84.
329. SAS Statistical Software. www.SAS.com
330. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 1995;274:645-50.
331. Anonymous. The quality of diagnostic tests statement, the CONSORT statement. www.consort-statement.org
332. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig JG, Moher D, Rennie D, De Vet HC, for the STARD steering group. Education and Debate. Towards Complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4.
333. Delong ER, Delong DM. Comparing the areas under two or more correlated receiver operated characteristic curves; a nonparametric approach. Biometrics 1988;44:837-45.
334. Barnett DV. Simultaneous pairwise linear structural relationships. Biometrics 1969;28:129-42.
335. Hoetker G. The use of logit and probit models in strategic management research. Strat Mgmt J 2007;28:331-43.
336. McGee WT, Horswell JL, Calderon J, Janvier G, Van Severen T, Van den Berghe G, Kozikowski L. Validation of a continuous arterial pressure-based cardiac output measurement: a multicenter, prospective trial. Critical Care 2007;11: R 105; pp 1-7.
337. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-10.
338. Linnet K. Performance of Deming regression analysis in case of miss-specified analytical error in method comparison studies. Clin Chem 1998;44:1024-31.
339. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem 1983;21:709-20.
340. Guidelines for global application developed by the Clinical and Laboratory Standards Institute. www.techstreet.com.
341. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 1995;274:645-50.
342. Anonymous. The quality of diagnostic tests statement, the CONSORT statement. www.consort-statement.org
343. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig JG, Moher D, Rennie D, De Vet HC, for the STARD steering group. Education and Debate. Towards Complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4.
344. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large scale replication study. JAMA 2007;297:1551-61.
345. Barnett DV. Simultaneous pairwise linear structural relationships. Biometrics 1969;28:129-42.
346. Delong ER, Delong DM. Comparing the areas under two or more correlated receiver operated characteristic curves; a nonparametric approach. Biometrics 1988;44:837-45.
347. Hanley JA, McNeil BJ. The meaning and use of the area under curve under a receiver operating characteristic (ROC) curve. Diag Radiol 1982;143:29-36.
348. Lee J, Koh D, Ong CN. Statistical evaluation of agreement between two methods for measuring a quantitative variable. Comput Biol Med 1989;19:61-70.
349. Bland JM, Altman DG. Comparing two methods of clinical measurement: a personal history. Int J Epidemiol 1995;24:s7-s14.
350. Imburt-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, Devers L. Hainque B, Mecardier A, Poynard T. Intra-laboratory analytical variability of biochemical markers of fibrosis and activity and reference ranges in healthy blood donors. Clin Chem Lab Med 2004;42:323-33.
351. Pratt Cm, Moye LA. The Cardiac Arrhythmias Suppression Trial. Circulation 1995;91:245-7.
352. Canner PL, Berg KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald F. Fifteen year mortality of the Coronary Drug Project. J Am Coll Cardiol 1986;8:1245-55.
353. Riggs P et al. Osteoporosis in postmenopausal women. N Engl J Med 1990;32:802-9.
354. Fleming TR, De Mets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
355. Boissel JP, Collet Hc. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992;43:235-44.
356. Philips A, Haudiquet V. The International Conference of Harmonisation (ICH) Guideline E9, Statistics Principles for Clinical Trials. Stat Med 2003;22:1-11.
357. Cleophas TJ. Clinical trials: a new method for assessing accuracy of diagnostic tests. Clin Res Reg Aff 2005;22:93-101.
358. Chen SX, Leung DH, Qin J. Information recovery in a study with surrogate endpoints. J Am Stat Assoc 2003;10:7-18.
359. Riegelman RK. Studying a study and testing a test. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
360. Kassaï B, Shah NR, Leizorovicz A, Cucherat M, Gueyffier F, Boissel JP. The true treatment benefit is unpredictable in clinical trials using surrogate outcome measures with diagnostic tests. J Clin Epidemiol 2005;58:1042-51.
361. th Edition, McGraw-Hill, New York, 1997 pp 5-27.
362. Hoetker G. The use of logit and probit models in strategic management research: critical issues. Strat Mgmt J 2007;28:331-43.
363. SPSS Statistical Software 13.0, Chicago, IL, USA, 2000.
364. Anonymous. Distinguishing between random and fixed variables, effects and coefficients. Newson, USP 656 Winter 2006, p1-3.
365. Campbell MJ. Random effects models. In: Statistics ar square two, second edition. Editor Campbell MJ. Blckwell Publishing, BMJ Books, Oxford UK, 2006, pp 67-83.
366. Gao S. Special models for sampling survey. In: Advanced Medical Statistics, first edition. Editors Lu Y, Fang J. World Scientific, New Jersey, 2003, pp 685-709.
367. Anonymous Variance components and mixed models. http://www.statsoft.com/ textbook/stvarcom.html
368. Anonymous. Random effects models. Wikipedia, the free encyclopedia. en. wikipedia.org/wiki/random-effects-models.html
369. Brier ME, Aronoff GR. Application of artificial neural networks to clinical pharmacology. Int J Clin Pharmacol Ther. 1996 Nov; 34:510-4.
370. Dalla Costa T, Nolting A, Rand K, Derendorf H. Pharmacokinetic- pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther. 1997 Oct; 35:426-33.
371. Mahmood I. Center specificity in the limited sampling model (LSM): can the LSM developed from healthy subjects be extended to disease states? Int J Clin Pharmacol Ther. 2003 Nov; 41:517-23.
372. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997 Oct; 35:401-13. Review.
373. Lima JJ, Beasley BN, Parker RB, Johnson JA. A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. Int J Clin Pharmacol Ther. 2005 Apr; 43(4):187-94.
374. Lotsch J, Kobal G, Geisslinger G. Programming of a flexible computer simulation to visualize pharmacokinetic-pharmacodynamic models. Int J Clin Pharmacol Ther. 2004 Jan; 42:15-22.
375. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007 Jun; 45:335-44.
376. Hays WL. Random effects and mixed models, chapter 13. In: Statistics, 4th edition, Holt, Rhinehart and Winnston Inc, Chicago, 1988, pp 479-543.
377. SPSS Statistical Software. http://www.spss.com
378. Boeckman AJ, Sheiner LB, Beal SL. NONMEM User's Guide. San Francisco: NONMEM Project Group, University of California, 1992, Book.
379. Zwinderman AH, Cleophas TJ, Van Ouwerkerk B. Clinical trials do not use random samples anymore. Clin Res Reg Affairs 2006;23:85-95.
380. Ulam N, Ulam S. The Monte Carlo method. J Am Stat Assoc 1949;44:335-41.
381. Vieira JW, Lima FR, Kramer R. A Monte Carlo approach to calculate dose distribution around the lineal brachytherapy sources. Cell Mol Biol 2002;48:445-50.
382. Haidekker YG. Trans-illumination optical tomography of tissue-engineered blood vessels: a Monte Carlo simulation. Appl Opt 2005;44:4265-71.
383. Upton RN, Ludbrook GL. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs-method development and application in sheep. BMC Pharmacol 2005;5:1471-81.
384. Nijhuis RL, Stijnen T, Peeters A, Witteman JC, Hofman A, Hunink MG. Apparent and internal validity of a Monte Carlo-Markow model for cardiovascular disease in a cohort follow-up study. Med Dec. Making 2006;26:134-44.
385. Woller J. The basics of Monte Carlo Simulation (1996). http://www.chem.unl.edu/zeng/joy/mclab/mcintro.html
386. SPSS Statistical Software. http://www.spss.com
387. Efron B, Tibshirani RJ. An introduction to the bootstrap. Chapman & Hall, 1993, New York, USA.
388. S-plus. http://www.mathsoft.com/splus
389. StatsDirect. http://www.camcode.com
390. StatXact. http://www.cytel.com/products/statxact/statact1.html
391. True Epistat. http://ic.net/~biomware/biohp2te.htm
392. BUGS y WinBUGS. http://www.mrc-bsu.cam.ac.uk/bugs
393. R. http://cran. r-project.org
394. SAS. http://www.prw.le.ac.uk/epidemiol/personal/ajs22/meta/macros.sas
395. Gardner MJ, Altman DG. Confidence in analysis. Statistical software edited by BMJ, 1989, ISBN 07279 0222-9.
396. Shao J, Tu D. The jackknife and bootstrap. Springer-Verlag, New York, 1995.
397. Fishman GS. Monte Carlo, concepts, algorithms and applications. Springer-Verlag, New York, 1996.
398. Ordronaux J. The jurisprudence of medicine in relation to the law of contracts, torts and evidence. The Lawbook Exchange, LTD, 1869.
399. Paget MA, The unity of mistakes, a phenomenological interpretation of medical work. Contemporary Sociology 1990;19:118-9.
400. Lambert V. Improving safety, reducing use. FDA Consumer 1992; October issue pp 1-5.
401. Anonymous. Beds in hospital, nursing homes and home health care. Drugs & Health products. 2001; May issue pp 2-6.
402. SPSS Statistical Software. http://www.spss.com
403. S-plus. http://www.mathsoft.com/splus
404. StatsDirect. http://www.camcode.com
405. StatXact. http://www.cytel.com/products/statxact/statact1.html
406. True Epistat. http://ic.net/~biomware/biohp2te.htm
407. BUGS y WinBUGS. http://www.mrc-bsu.cam.ac.uk/bugs
408. R http://cran. r-project.org
409. SAS. http://www.prw.le.ac.uk/epidemiol/personal/ajs22/meta/macros.sas
410. Cleophas TJ, Zwinderman AH, Cleophas TF. Statistics applied to clinical trials: self-assessment book. Ed by Cleophas TJ, Kluwer Academic Publishers, Boston, MA, 2002.
411. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and angina pectoris in patients with low ejection fraction. Lancet 1992;340:1173-8.
412. Collaborative Group of Primary Prevention Project. Low dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-75.
413. Staedke SG, Kanga MR, Dorsey G, et al. Amiodaquine, sulfadioxone/ pyrimethamine and combination therapy for treatment of falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 2001;358:368-74.
414. Shepherd J, Blauw GJ, Murphy MB, et al, on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease: a randomised trial. Lancet 2002;360:1623-30.
415. Wallenstein L, Wilcox RG, Weaver WD, et al, for the ESTEEM investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction. Lancet 2003;362; 789-97.
416. Jochan D, Richter A, Hofmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumor progression in patients with renal cell carcinoma. Lancet 2004;362:594-9.
417. Andrews DW, Scott CB, Speranto PW, et al. Whole brain irradiation therapy with or without stereotactic radiosurgery boost for patients with 1-3 brain metastases. Lancet 2004;363:1665-72.
418. Ferreira-Gonzalea I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786-8.
419. Horng S, Grudy C. Misunderstanding of clinical research. Ethics and Human Research 2003;25:11-6.
420. Fetting JH, Siminoff CA, Piantadosi S et al. effects of patients' expectations of benefit with standard breast cancer adjuvant therapy on participants in clinical trials. J Oncol 1990;8:1476-82.
421. Anonymous. Patients' demands for prescriptions in primary care. Br Med J 1995;310:1084-5.
422. Kirkwood BR, Sterne J A C. Dose response relationships (trends). In: Medical statistics. Blackwell Science Malden. MA, 2003, pp 336-8.
423. SPSS Statistical Software. http://www.spss.com
424. Microsoft's Excel. www.microsoft.com
425. SAS. http://www.prw.le.ac.uk/epidemiol/personal/ajs22/meta/macros.sas
426. Guyatt G, Rennie D. Users guide to the medical literature-a manual for evidence based clinical practice by the Evidence-Based Medicine Working Group Cicago, USA. AMA Press. 2001; pp 356-7.
427. Bland JM, Altman DG. The odds ratio. BMJ 2000;320:1468.
428. BUGS y WinBUGS. http://www.mrc-bsu.cam.ac.uk/bugs
429. http://cran.r-project.org
430. S-plus. http://www.mathsoft.com/splus
431. Stata. http://www.stata.com
432. StatsDirect. http://www.camcode.com
433. StatXact. http://www.cytel.com/products/statxact/statact1.html
434. True Epistat. http://ic.net/~biomware/biohp2te.htm
435. SAS. http://www.prw.le.ac.uk/epidemiol/personal/ajs22/meta/macros.sas
436. SPSS Statistical Software. http://www.spss.com
437. Zwinderman AH, Niemeijer MG, Kleinjans HA, Cleophas TJ. Application of item response modelling for quality of life assessments: effect of two nitrate treatment regimens in stable angina pectoris. In: What should a clinical pharmacologist know to start a clinical trial, Kuhlmann and Mrozikiewicz, editors. Zuckschwerdt Verlag, New York, 1998, pp 40-8.
438. Zwinderman AH. Subgroup analysis using multiple regression, confounding, interactions, synergism. In: Statistics applied to clinical trials. Edited by Cleophas, Zwinderman and Cleophas, Springer 2006; Dordrecht, Neth, pp 125-40.
439. Cleophas TJ, Zwinderman AH. Statistical primer for cardiovascular research, meta-analysis. Circulation 2007;115:2870-5.
440. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
441. Cleophas TJ. Problems with regression modeling for the analysis of clinical trials. Int J Clin Pharmacol Ther 2005;43:23-9.
442. Anonymous. Explanation of the quadratic approximation. www.math.tamu.edu/~kfu/Quadratic Approximation.pdf
443. Cleophas TJ. The sense and non-sense of regression modeling for increasing precision of clinical trials. Clin Pharmacol Ther 2003;74:295-7.
444. Excel by Windows. http://www.excel.com
445. SAS Statistical Software 2000 New York, NY, USA.
446. SPSS Statistical Software 2000 Chicago, IL, USA.
447. Cleophas TJ. Methods for improving drug trials. Clin Chem Lab Med 1999;37:1035-41.
448. Cleophas TJ, Zwinderman AH. Limits of randomized trials, proposed alternative designs. Clin Chem Lab Med 2000;38:1217-23.
449. Farewell VT, Dángio GJ. Report of the National Wilmś Tumor Study Group. Biometrics 1981;37:169-76.
450. Sacks H, Chalmers TC, Smith H. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233-40.
451. Pocock SJ 1988 Clinical trials. A practical approach. Wiley, New York, USA
452. Whitehead J 1998 Planning and Evaluating Sequential Trials (PEST, version 3). Reading: University of Reading (www.reading.ac.uk/mps/pest/pest.html)
453. Lauter J. Exact t and F-tests for analyzing studies with multiple endpoints. Biometrics 1996;52:964-70.
454. Medical Research Council. Streptomycin Treatment of pulmonary tuberculosis. Br Med J 1948;2:769-82.
455. Yusuf S, Pepine CJ, Garces C. Effect of enalapril on myocardial infarction and angina pectoris in patients with low ejection fraction. Lancet 1992;340:1173-8.
456. Campbell JP, Maxey VA, Watson WA. Hawthorne effect: implications for prehospital research. Ann Emergency Med 1995;26:590-4.
457. Cleophas TJ. The use of a placebo-control group in clinical trials. Br J Clin Pharmacol 1997;43:219-21.
458. Anonymous. International guidelines for good clinical practice. Ed: NEFARMA (Netherlands Association of Pharmaceutical Industries), Utrecht, Netherlands, 1997.
459. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-82.
460. Cleophas TJ, Zwinderman AH, Cleophas TF. 2002 Statistics Applied to Clinical Trials, Self-assessment Book. Kluwer Academic Publishers, Boston, USA
461. Montaner JS, O'Shaughnessy MV, Schechter MT. Industry-sponsored clinical research: a double-edged sword. Lancet 2001;358:1893-5.
462. Diamant JC. The revised Declaration of Helsinki - is justice served. Int J Clin Pharmacol Ther 2002;40:76-83.
463. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probsfield J. Blood pressure reduction and cardiovascular risk in HOPE Study. Lancet 2001;358:2130-1.
464. 7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
465. Meyer FP, Cleophas TJ. Meta-analysis of beta-blockers in heart failure. Int J Clin Pharmacol Ther 2001;39:561-563 and 39:383-8
466. Cleophas TJ, Zwinderman AH. Efficacy of HMG-CoA reductase inhibitors dependent on baseline cholesterol levels, secondary analysis of the Regression Growth Evaluation Statin Study (REGRESS). Br J Clin Pharmacol 2003;56:465-6.
467. Relman AJ, Cleophas TJ, Cleophas GI. The pharmaceutical industry and continuing medical education. JAMA 2001;286:302-4.